Satellos Q2 loss widens to $11.7M, EPS misses estimates
Satellos Bioscience's Q2 2026 results show a net loss of $11.7 million, driven by increased R&D spending on Phase 2 trials for its lead DMD candidate. The EPS miss of $(0.56) against a $(0.45) estimate underscores rising operational costs. With $61.8 million in cash, the company maintains a runway through 2027 while advancing clinical programs.
*this image is generated using AI for illustrative purposes only.
Satellos Bioscience Inc (NASDAQ: MSLE, TSX: MSCL) reported a net loss of $11.7 million ($0.56 per share) for the second quarter ended June 30, 2026. The per-share loss missed the analyst consensus estimate of $(0.45) by 24.44 percent. This represents a 43.59 percent increase in losses compared to $(0.39) per share in the same period last year, when the company recorded a net loss of $5.6 million. The clinical-stage biopharma company also announced it received FDA Fast Track Designation for its lead drug candidate, SAT-3247, aimed at treating Duchenne muscular dystrophy (DMD).
As of June 30, 2026, Satellos held $61.8 million in cash, cash equivalents, and short-term investments, up from $27.7 million at the end of December 2025. The increase reflects proceeds from an equity offering completed in February 2026, partially offset by operational expenditures. Management stated this capital position is expected to provide a runway through 2027.
Financial Performance
Total operating expenses rose significantly as the company scaled its clinical development programs. Research and development (R&D) expenses increased to $9.6 million in Q2 2026 from $4.4 million in Q2 2025. This growth was driven by costs associated with the TRAILHEAD and BASECAMP Phase 2 studies, along with chemistry and manufacturing controls for drug production.
General and administrative (G&A) expenses also climbed to $2.5 million from $1.9 million year-over-year, attributed to increased headcount, professional fees for public reporting obligations, and Nasdaq listing costs.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Net Loss: | $(11.7) million | $(5.6) million | Widened |
| EPS: | $(0.56) | $(0.39) | Missed Est. |
| R&D Expenses: | $9.6 million | $4.4 million | +$5.2 million |
| G&A Expenses: | $2.5 million | $1.9 million | +$0.6 million |
| Cash Position: | $61.8 million | $27.7 million | +$34.1 million |
What the Numbers Show
The widening net loss correlates directly with the acceleration in clinical trial spending. R&D expenses constituted approximately 82% of total operating expenses (R&D plus G&A) in Q2 2026, compared to roughly 70% in Q2 2025. This shift indicates that the majority of the company’s burn rate is now directed toward advancing its primary asset, SAT-3247, rather than administrative overhead. The miss against analyst estimates highlights the higher-than-anticipated cost intensity of scaling these Phase 2 trials.
Clinical Updates
Satellos provided updates on its two active Phase 2 trials for SAT-3247:
- BASECAMP (Pediatric): The trial is actively enrolling 51 ambulatory boys aged 7–9 with DMD. The company expects to report clinical data from this study in the fourth quarter of 2026.
- TRAILHEAD (Adult): Six-month follow-up data from four participants showed stable strength, reduced muscle fat fraction via MRI, and improved quality of life. The open-label study plans to enroll up to 30 participants in the U.S. and Australia, with an update expected in Q4 2026.
Additionally, Satellos remains on track to submit an Investigational New Drug (IND) application to the FDA for facioscapulohumeral muscular dystrophy (FSHD) and launch a related Phase 2 trial later in 2026.
How might the FDA Fast Track designation for SAT-3247 influence Satellos' ability to secure strategic partnerships or accelerate regulatory timelines for Duchenne muscular dystrophy?
Given the 24% miss on EPS estimates, will Satellos need to raise additional capital before its stated 2027 cash runway expires to fund the upcoming Phase 2 data readouts?
What specific clinical endpoints in the Q4 2026 BASECAMP and TRAILHEAD trials are most critical for determining whether SAT-3247 can progress to Phase 3 development?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
